2. Department of Biochemistry and Nutrition, Nigerian Institute of Medical Research ,Yaba, Lagos, Nigeria.
Objective: This study investigated the effects of atorvastatin and artemisinin based combination therapies (ACTs), administered individually and orally co-administered on some hepatotoxic biomarkers and parasitemia counts in Plasmodium berghei NK65 strain infected mice.
Methods: Twenty-five male Swiss albino mice were randomly distributed in five groups; Group I : ‘parasitized mice administered with atorvastatin’. Group II; ‘parasitized mice administered with atorvastatin + artesunate. Group III; ‘parasitized mice administered with atorvastatin + artemether. Group IV; ‘parasitized negative control group administered normal saline only’. Group V; ‘parasitized positive control group administered chloroquine’.
Results: Plasma aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphate (ALP) and procalcitonin (PRO) activities were significantly reduced (p<0.05) in atorvastatin + artesunate, atorvastatin + artemether and chloroquine treated groups when compared with the negative control and atorvastatin treated group. Furthermore, the parasitemia count in Plasmodium berghei infected mice was suppressed in mice treated with atorvastatin + artesunate, atorvastatin + artemether and chloroquine when compared to mice treated with atorvastatin alone.
Conclusion: The data from this study indicates that atorvastatin has a moderate potential in the clearance ability of Plasmodium berghei NK65 parasites and elicits hepatic and renal injury. It also indicates that the co-administration of artesunate and artemether with atorvastatin in the treatment of malaria could be beneficial with less severe hepatic and renal events.
Keywords: ACTs, Atorvastatin, Aspartate Transaminase, Alanine Transaminase, Alkaline Phosphatase, Procalcitonin, Plasmodium berghei